Durability of Antiviral Activity in Chronic HBV Patients Who Showed Complete Response in L-FMAU-301,302 or 303 Trial

Completed

• Conditions: Hepatitis B

• Registration Number: NCT00362674
• Lead Sponsor: Bukwang Pharmaceutical

Brief Summary

The purpose of this study is to evaluate the durability of antiviral activity in chronic hepatitis B patients who showed complete response in L-FMAU-301,L-FMAU-302 or L-FMAU-303 trial.

Detailed Description

Not available

Study Timeline

• Study Start: 2005-06
• Study First Submitted: 2006-08-08
• Study First Submitted QC: 2006-08-08
• Study First Posted: 2006-08-10
• Status Verified: 2010-12
• Last Update Submitted: 2017-01-30
• Last Update Posted: 2017-02-01

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

1. The patients who have completed L-FMAU-301, L-FMAU-302 or L-FMAU-303.
2. Patients who have showed complete response (ALT normalization and HBV DNA <4,700 copies/mL in L-FMAU-301 or L-FMAU-302, in addition, HBeAg seroconverted to anti-HBe at the last two visits in L-FMAU-301) after completion of L-FMAU-301 or L-FMAU-302 and treated with the clevudine.
3. Patients who have showed complete response (ALT normalization and HBV DNA <4,700 copies/mL, in addition HBeAg seroconverted to anti-HBe at the last two visits who showed HBeAg positiv at baseline) after completion of L-FMAU-303
4. Patients who were able to give written informed consent prior to study start and to comply with the study requirements.
5. Patients with bilirubin levels less than 2.0 mg/dL, prothrombin time of less than 1.7 (INR), and a serum albumin level of at least 3.5 g/dL at the last visit in L-FMAU-301, L-FMAU-302 or L-FMAU-303.

Exclusion Criteria

1. Patients who have showed complete response but previously treated with placebo in the L-FMAU-301, L-FMAU-302.
2. Patients who were currently receiving antiviral, immunomodulatory or corticosteroid therapy.
3. Patients previously treated with interferon, lamivudine, lobucavir, famciclovir, adefovir or any other investigational nucleoside for HBV infection.
4. Patients with a history of ascites, variceal hemorrhage or hepatic encephalopathy.
5. Patients co-infected with HCV, HDV or HIV.
6. Patients with a liver mass (hemangioma, nodule), biliary diseases except asymptomatic GB stone during the L-FMAU-301, L-FMAU-302 or L-FMAU-303.
7. Patients who were pregnant or breast-feeding.
8. Patients with a significant gastrointestinal, renal, hepatic (decompensated), biliary diseases except asymptomatic GB stone, bronchopulmonary, neurological, cardiovascular, oncologic or allergic disease. The patients with a benign tumor were excluded if judged by an investigator that the continuation of study would be interfered by benign tumor.
9. Patients who were not suitable to the study if judged by an investigator.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Trial Locations

Locations (27)

Keimyumg University Dongsan Medical Center; 🇰🇷 Jung-gu,, Daegu, Korea, Republic of

Korea University Guro Hospital; 🇰🇷 Seoul, Guro-gu, Korea, Republic of

St. Mercy's Hospital; 🇰🇷 Bupyoung-dong, Bupyoung-gu, Incheon, Korea, Republic of

Inha University Hospital; 🇰🇷 Sinhung-dong, Jung-gu, Incheon, Korea, Republic of

Wonkwang University Hospital; 🇰🇷 Iksan-City, Jeonbuk, Korea, Republic of

Chonbuk National University Hospital; 🇰🇷 Jeonju-city, Jeonbuk, Korea, Republic of

Seoul National University Hospital; 🇰🇷 Seoul, Jongno-Gu, Korea, Republic of

National Cancer Center; 🇰🇷 Ilsan-gu, Kyounggi-do, Korea, Republic of

St. Holly Family Mary's Hospital; 🇰🇷 Pucheon, Kyounggi-do, Korea, Republic of

Pochon CHA University Hospital; 🇰🇷 Seongnam-gu, Kyounggi-do, Korea, Republic of

Scroll for more (17 remaining)